09:23 AM EDT, 06/23/2025 (MT Newswires) -- GeneDx's ( WGS ) Fabric Genomics has entered into a partnership with Galatea Bio to enhance genetic testing by combining rare variant analysis and polygenic risk scoring to assess susceptibility to common diseases, the companies said Monday.

The initial offering will feature a cardiovascular gene panel based on American Heart Association guidelines, with risk scores for coronary artery disease, cholesterol traits, atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism.

A second offering will add hereditary cancer panels with polygenic risk scores for breast, colorectal and prostate cancers.

The companies said the approach integrates Fabric Genomics' clinical reporting capabilities with Galatea's ancestry-adjusted polygenic risk-scoring technology.

Financial terms of the partnership were undisclosed.